BOSTON–(BUSINESS WIRE)–Catabasis Prescribed pills, Inc. (NASDAQ:CATB), a scientific-stage biopharmaceutical firm, introduced this day that it has named Ben Harshbarger as Senior Vice President, Approved Counsel. Mr. Harshbarger brings to Catabasis more than 20 years of expertise at industrial-stage pharmaceutical and biotechnology companies.
“Ben brings to Catabasis in depth senior excellent and compliance expertise in the pharmaceutical industry, including in product launches, and the transition from pre-industrial to industrial-stage. His deep expertise can be in particular treasured in the coming months as we prepare for high-line results from the Segment 3 PolarisDMD trial and the most likely commercialization of edasalonexent for the medication of Duchenne muscular dystrophy,” mentioned Jill C. Milne, Ph.D., Chief Executive Officer of Catabasis. “We’re satisfied that Ben has joined the crew and can maintain to tranquil be leveraging his operating and rare illness expertise.”
“I’m satisfied to be becoming a member of the Catabasis crew as we work against making a brand new medication option accessible to the Duchenne community,” mentioned Mr. Harshbarger. “Catabasis is making prepared for the most likely future transition to a industrial group, and I’m angry to hitch at this kind of truly well-known time.”
Mr. Harshbarger most no longer too prolonged ago served because the Intervening time Chief Executive Officer and Approved Counsel at Novelion Therapeutics, Inc., the mum or dad firm of Aegerion Prescribed pills, Inc. Ahead of that, he served in numerous excellent roles at Aegerion Prescribed pills, Inc., including as Deputy Approved Counsel, VP, EMEA Honest Counsel, and Acting Approved Counsel and Approved Counsel. As Acting Approved Counsel and Approved Counsel, he performed a serious position in revamping Aegerion’s compliance program. Mr. Harshbarger has moreover held senior excellent positions at Cubist Prescribed pills, Inc., Viacell, Inc. and Biogen, Inc. Mr. Harshbarger holds his JD from Boston College Regulation College, and his BA from the College of Richmond.
About Edasalonexent (CAT-1004)
Edasalonexent (CAT-1004) is an investigational oral dinky molecule designed to inhibit NF-kB that is being developed as a most likely foundational remedy for all sufferers plagued by DMD, no topic their underlying mutation. In DMD the lack of dystrophin ends in chronic activation of NF-kB, which is a key driver of skeletal and cardiac muscle illness progression. Our ongoing global Segment 3 PolarisDMD trial is evaluating the efficacy and safety of edasalonexent for registration capabilities. Edasalonexent is moreover being evaluated in the GalaxyDMD open-label extension trial. In our MoveDMD Segment 2 trial and open-label extension, we seen that edasalonexent preserved muscle function and critically slowed illness progression when in contrast to charges of alternate in a withhold an eye on interval, and critically improved biomarkers of muscle health and irritation. The FDA has granted orphan drug, rapidly note, and rare pediatric illness designations and the European Commission has granted orphan medicinal product designation to edasalonexent for the medication of DMD. For a summary of scientific results, please accelerate to www.catabasis.com.
At Catabasis Prescribed pills, our mission is to lift hope and life-altering therapies to sufferers and their families. Our lead program is edasalonexent, an NF-kB inhibitor in Segment 3 pattern for the medication of Duchenne muscular dystrophy. For more details on edasalonexent and our Segment 3 PolarisDMD trial, please accelerate to www.catabasis.com.
Forward Making an try Statements
Any statements on this press liberate about future expectations, plans and prospects for the Company, including statements about the Company’s global Segment 3 PolarisDMD trial in DMD to review the efficacy and safety of edasalonexent for registration capabilities, the predicted timing for high-line results, the most likely timing for the submitting of an NDA, the Company’s deliberate transition to a industrial-stage group and varied statements containing the words “believes,” “anticipates,” “plans,” “expects,” “would possibly per chance fair” and an identical expressions, characterize forward-searching statements throughout the that approach to the Non-public Securities Litigation Reform Act of 1995. Proper results would possibly per chance fair differ materially from those indicated by such forward-searching statements on legend of different well-known factors, including: risks and uncertainties linked to the affect of the COVID-19 pandemic, uncertainties inherent in the initiation and completion of preclinical learn and scientific trials and scientific pattern of the Company’s product candidates; whether intervening time results from a scientific trial can be predictive of the final results of the trial or the outcomes of future trials; expectations for regulatory approvals to conduct trials or to market merchandise; availability of funding sufficient for the Company’s foreseeable and unforeseeable operating charges and capital expenditure necessities; varied matters that would possibly per chance maintain an affect on the provision or industrial most likely of the Company’s product candidates; and general economic and market instances and varied factors discussed in the “Possibility Factors” piece of the Company’s Quarterly Myth on Procure 10-Q for the interval ended March 31, 2020, which is on file with the Securities and Change Commission, and in varied filings that the Company would possibly per chance fair make with the Securities and Change Commission in the prolonged bustle. Moreover to, the forward-searching statements included on this press liberate picture the Company’s views as of the date of this press liberate. The Company anticipates that subsequent events and developments will situation off the Company’s views to alternate. On the other hand, while the Company would possibly per chance fair elect to update these forward-searching statements at some level in the prolonged bustle, the Company namely disclaims any responsibility to invent so. These forward-searching statements can maintain to tranquil no longer be relied upon as representing the Company’s views as of any date subsequent to the date of this liberate.